Targeted Oncology5h
Elraglusib Gains FDA Rare Pediatric Disease Designation in Ewing Sarcoma
Elraglusib is undergoing investigation in an open-label, multicenter, phase 1/2 trial for the treatment of patients with ...
Targeted Oncology6h
Mapping ctDNA Shedding Differences in GU Cancers With MRD Testing
Arnab Basu, MD, MPH, FACP, explains why sensitivity might be higher in urothelial cancer vs other genitourinary cancers.
Targeted Oncology12h
Nivolumab-Chemotherapy Combo Boosts PFS in cHL, Poised for Standard Use
The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, ...